RSC Bay Area Is First in the Nation to Deploy FDA-Cleared AI for Embryo Assessment by Alife Health, Pioneering a New Standard in IVF Care

RSC Bay Area Is First in the Nation to Deploy FDA-Cleared AI for Embryo Assessment by Alife Health, Pioneering a New Standard in IVF Care

RSC Bay Area Is First in the Nation to Deploy FDA-Cleared AI for Embryo Assessment by Alife Health, Pioneering a New Standard in IVF Care

https://www.prnewswire.com/news-releases/rsc-bay-area-is-first-in-the-nation-to-deploy-fda-cleared-ai-for-embryo-assessment-by-alife-health-pioneering-a-new-standard-in-ivf-care-302787801.html

Publish Date: 2026-06-02 07:00:00

Source Domain: www.prnewswire.com

In a first for U.S. reproductive medicine, RSC Bay Area and Alife Health bring AI-powered embryo assessment from clinical trial to patient care — setting a new benchmark for what technology-forward fertility treatment looks like.

SAN FRANCISCO and LOS ANGELES, June 2, 2026 /PRNewswire/ — Alife Health (Alife), a health tech company advancing fertility care through artificial intelligence, and RSC Bay Area, a US Fertility network partner and one of the country’s leading fertility practices, today announced that RSC Bay Area is the first clinic in the United States to bring Alife Health’s Embryo Predict™ into routine clinical use. The deployment comes days after the tool received clearance from the U.S. Food and Drug Administration. The milestone is the product of a deliberate, multi-year partnership between RSC Bay Area’s parent network US Fertility and Alife, and it positions RSC Bay Area at the forefront of AI adoption in IVF.

The Problem Embryo Predict Solves
For decades, selecting which embryo to transfer has been one of the most consequential — and most subjective — decisions in IVF. Even among the most experienced embryologists, variability in this decision is a recognized challenge. Embryo Predict addresses that directly. Using artificial intelligence trained on thousands of embryo images, it analyzes blastocysts and generates a data-driven score that provides embryologists with an objective, real-time insight to assist with transfer decisions. A large multi-center randomized trial, in which RSC Bay Area participated, demonstrated the tool’s ability to assist with embryo selection and led to the tool being the first IVF AI to achieve FDA clearance.

A Partnership Built for This Moment
RSC Bay Area’s ability to move immediately following FDA clearance is no accident. US Fertility, the nation’s largest partnership of physician-owned fertility practices, has maintained an active…

Source